Wednesday, July 8, 2026

Patent intelligence · US

US 12391732

Articles comprising a silk polypeptide for antigen delivery

granted A61KA61K2039/6031A61K2039/627A61K38/00
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 19
Applicant portfolio 138
Patent details — US 12391732
Jurisdiction
US
Status
granted
Grant date
Aug 19, 2025
Expiration
Aug 14, 2045
Claims
8
CPC classes
A61K, A61K2039/6031, A61K2039/627, A61K38/00
View on Google Patents ↗

Quick answer

US 12391732 (Articles comprising a silk polypeptide for antigen delivery) is held by Ludwig-Maximilians-Universitat Munchen. Status: granted. Granted Aug 19, 2025. Expires Aug 14, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
8
CPC classes
A61K, A61K2039/6031, A61K2039/627, A61K38/00, A61K39/385, A61K47/42

More from Ludwig-Maximilians-Universitat Munchen

Related pharmaceutical patents in our USPTO index.

  1. US 12379385

    Methods of treating patients afflicted with irritable bowel syndrome, inflammatory bowel disease or chronic gastrointestinal functional disorders based on assessment of intestinal barrier function

    Maximus Diagnostic Technologies LLC · Expires Jul 31, 2045

    granted
  2. US 12318397

    Methods and compositions for testosterone production

    Maximus Health, Inc. · Expires May 29, 2045

    granted
  3. US 12290524

    Methods and compositions for testosterone production

    Maximus Health, Inc. · Expires May 1, 2045

    granted
  4. US 12171837

    Chemoselective thiol-conjugation with alkene or alkyne-phosphonamidates

    Ludwig-Maximilians-Universitat Munchen · Expires Dec 19, 2044

    granted
  5. US 12168718

    Thermogelling supramolecular sponge as self-healing and biocompatible hydrogel

    Julius-Maximilians-Universitat Wurzburg · Expires Dec 12, 2044

    granted
  6. US 12144876

    Security mechanisms for radiopharmaceutical elution system and elution process

    Jubilant Draximage Inc. · Expires Nov 14, 2044

    granted
  7. US 12133890

    Antigen-binding polypeptide targeting B7H3 and application thereof

    NINGBO T-MAXIMUM BIOPHARMACEUTICALS CO., LTD. · Expires Oct 31, 2044

    granted

Frequently asked questions

What is US patent 12391732?

US 12391732 (Articles comprising a silk polypeptide for antigen delivery) is held by Ludwig-Maximilians-Universitat Munchen. Status: granted. Granted Aug 19, 2025. Expires Aug 14, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12391732?

Ludwig-Maximilians-Universitat Munchen is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 138 pharmaceutical patents for this assignee.

When does US 12391732 expire?

Our index shows an expiration date of Aug 14, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.